Of the fifteen of the well-documented HER2-positive cases, eleven patients received HER2 targeted therapy for primary breast cancer (HER2-directed therapy was not available until 2009 in adjuvant or neoadjuvant settings). This evidence concerns the gene ERBB2 and breast cancer.